Chronic Kidney Disease (CKD)
Conditions
Interventions
additional medication of HCTZ (12.5mg/d) to valsartan (80mg/d, once in the morning) for 2 months
Sponsors
Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. received medical care at Nagoya City University Hospital; age of 20 or more y 2. CKD criteria based on K/DOQI 3. previous treatment with valsartan (80mg/d) for 2 months or more, office BP >130/80 on at least one occasion 4. documented informed concent
Exclusion criteria
Exclusion criteria: 1. previous treatment with ARB, other than valsartan, or diuretics 2 months before enrollment 2. contraindication to valsartan or HCTZ (history of allergic reaction to them, bilateral renal artery stenosis) 3. presence or possibility of pregnancy 4. HbA1c 9.0 or more % 5. GOT >100, or GPT >85 6. endocrine hypertension 7. accelerated o r malignant hypertension (progressive renal dysfunction with diastolic BP of >120-130 mmHg 8. serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 9. nephrotic syndrome (serum albumin <2.5 g/dl) 10. patients under hemodialysis therapy 11. any reason for ineligibility suggested by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in the night/day ratio ofmean arterial pressure (MAP) | — |
Secondary
| Measure | Time frame |
|---|---|
| office BP, night/day ratios of natriuresis and albuminuria, urinary angiotensinogen excretion rate, plasma catecholamines | — |
Countries
Japan
Contacts
Public ContactMichio Fukuda
Nagoya City University Graduate School of Medical Sciences Cardio-Renal Medicine and Hypertension
Outcome results
None listed